| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
It does not have a specific biological target for therapeutic use as it is a labeled metabolite. Its application is in analytical chemistry for the detection of banned antibiotics. It is a Drug Metabolite and serves as an analytical standard for mass spectrometry and chromatography.
|
|---|---|
| ln Vitro |
It is not evaluated for biological activity. Its chemical property is to serve as a tracer. It shows high chemical stability and is compatible with LC-MS/MS analysis. The deuterium labeling provides a mass shift of +4 Da compared to the non-labeled AOZ, allowing clear differentiation in mass spectrometry for precise quantification.
|
| ln Vivo |
Not applicable for therapeutic use. In vivo, the non-labeled parent drug (furazolidone) is metabolized to AOZ. The labeled standard (AOZ-d4) is used exclusively for ex vivo quantification of tissue residues of furazolidone in food safety and pharmacokinetic studies in research animals.
|
| Enzyme Assay |
For analytical protocol development, the standard is prepared as a certified reference solution (e.g., 100 microg/mL in acetonitrile). To establish a calibration curve in a non-cell matrix (e.g., blank fish tissue extract), serial dilutions are prepared in solvent. LC-MS/MS is performed with MRM transitions specific for both AOZ and AOZ-d4. The ratio of peak areas is used for quantification.
|
| Cell Assay |
In an in vitro assay, known amounts of the internal standard (e.g., 10 ng/mL) are spiked into a sample extract (e.g., from food or cell culture homogenate). This mixture is then analyzed using LC-MS/MS. By monitoring the signal of AOZ-d4, the recovery and matrix effects of the extraction process can be calculated. The specific MRM transition for d4 is m/z 106.1 [M+H]+.
|
| Animal Protocol |
For a typical animal study (e.g., monitoring drug residues), test animals are dosed with furazolidone. Tissues (liver, kidney, muscle) are harvested and homogenized. The stable isotope standard is added to the tissue homogenate. The sample undergoes protein precipitation, extraction, and purification by SPE. The final eluate is analyzed by LC-MS/MS to quantify the concentration of AOZ in the original tissue.
|
| ADME/Pharmacokinetics |
It is a stable compound with good shelf life. As a deuterated internal standard, it corrects for analyte loss during sample preparation (extraction, purification) and ionization suppression/enhancement in MS. The standard should be stored desiccated at +4degC or -20degC as directed.
|
| Toxicity/Toxicokinetics |
As an analytical standard, it is considered non-toxic at the concentrations used for analysis (typically ng/mL to ug/mL). Safety data relate to the solvent (e.g., acetonitrile). Standard laboratory safety precautions should be taken. It is not intended for in vivo dosing for any therapeutic purpose.
|
| References |
|
| Additional Infomation |
3-Amino-2-oxazolidinone-d4 is a VETRANAL™ analytical standard commonly used in food safety testing to comply with regulations for nitrofuran residues in animal products. It is crucial for accurate mass spectrometry quantification and is used in multi-residue analysis of nitrofuran metabolites in food products.
|
| Molecular Formula |
C3H2D4N2O2
|
|---|---|
| Molecular Weight |
106.11700
|
| Exact Mass |
106.068
|
| CAS # |
1188331-23-8
|
| Related CAS # |
3-Amino-2-oxazolidinone;80-65-9
|
| PubChem CID |
44118735
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
62-64°C
|
| LogP |
-0.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
7
|
| Complexity |
92.9
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C1(C(OC(=O)N1N)([2H])[2H])[2H]
|
| InChi Key |
KYCJNIUHWNJNCT-LNLMKGTHSA-N
|
| InChi Code |
InChI=1S/C3H6N2O2/c4-5-1-2-7-3(5)6/h1-2,4H2/i1D2,2D2
|
| Chemical Name |
3-amino-4,4,5,5-tetradeuterio-1,3-oxazolidin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.4233 mL | 47.1165 mL | 94.2329 mL | |
| 5 mM | 1.8847 mL | 9.4233 mL | 18.8466 mL | |
| 10 mM | 0.9423 mL | 4.7116 mL | 9.4233 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
